Parkinson's disease, a neurodegenerative disorder; and epilepsy, a group of diseases associated with recurrent seizures, which is caused by periodic episodes of repetitive, abnormal electrochemical disturbance in the central nervous system, beginning in the brain. The company also focuses on the development of gene transfers for the treatment of neurodegenerative and metabolic disorders, including Huntington's disease, depression, and metabolic syndrome or genetically-based obesity. Neurologix, Inc. was founded in 1999 and is based in Fort Lee, New Jersey.